Summary: Forbes publishes an overview of the announcement surrounding a successful confirmatory Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD). “The Phase 3 confirmatory results support the development of MDMA-assisted therapy as a potentially new breakthrough therapy to treat individuals with PTSD—a patient population that is often left to suffer for years,” says Amy Emerson, CEO of MAPS Public Benefit Corporation (MAPS PBC).